Canabo
Medical Inc. (TSX VENTURE: $CMM) (OTCQB: $AMDF) observational study finds
nearly fifty per cent drop in benzodiazepine use within months of #cannabis
treatment
Milestone study shows dramatic
reduction in pharmaceutical reliance among Canadian medical cannabis patients
TORONTO, ON - April 7, 2017
(Investorideas.com Newswire) Today, Canabo Medical Inc. (TSX VENTURE: CMM)
(OTCQB: CAMDF) ("Canabo" or the "Company") released the
results of a new, landmark observational study that connects doctor-supervised
medical cannabis treatments to a sharp drop in benzodiazepine reliance among
Canadian patients.
Research conducted over the past year
revealed that 40 per cent of patients who were prescribed medical cannabis to
treat pain and anxiety eliminated the use of benzodiazepines within 90 days.
That percentage increased to 45 per cent within a year of cannabis treatment.
The findings were announced by Dr. Neil Smith during a presentation at the
Canadian Consortium for the Investigation of Cannabinoids (CCIC) event in
Toronto.
Canabo, which operates 15 cannabinoid
clinics across Canada under the brand CMClinics, partnered with a consortium of
medical research experts to analyze data from more than 1,500 patients with the
aim of understanding how cannabis interacts with or lessens the need for
pharmaceutical treatments. Preliminary findings in late 2016 indicated a
downward trend in benzodiazepine use -- a trend that was confirmed after
additional investigation and included in the Reduction of Benzodiazepine Use in
Patients Prescribed Medical Marijuana report. The team responsible for the
peer-reviewed report has shared their findings with several Canadian medical
journals and details are expected to soon appear in the Dalhousie Medical
Journal.
In Canada, 10 per cent of the general
population use benzodiazepines daily, with common side-effects such as
sedation, dizziness, drowsiness, unsteadiness, headache and memory impairment.
Long-term benzodiazepine use is also associated with complications including
problems with concentration, tolerance, addiction and overdose.
"We wanted to take a close look
at the likelihood of continued benzodiazepine usage after commencing medical
cannabis treatments and to be perfectly honest, the results are extremely
promising," said Dr. Neil Smith, Executive Chairman of Canabo. "When
conducting this type of research, experts are typically encouraged by an
efficacy rate in the neighbourhood of 10 per cent. To see 45 per cent
effectiveness demonstrates that the medical cannabis industry is at a real watershed
moment."
Augmenting
pharmaceutical regimes with cannabinoid treatments
The study isolated a group of 146
patients from a database of individuals being treated for a wide variety of
pain and other disorders for approximately one-year. Each patient was referred
by a primary physician or specialist and thoroughly assessed by CMClinic's own
doctors before being prescribed cannabis as supplemental treatment. Additional
patient details include:
- The average age of the
sample of patients using benzodiazepines on initial contact with the
company is 48 years-old
- Nearly 43 per cent (42.9%)
of that group report a work status of either temporarily or permanently
disabled
- Nearly 60 per cent (59.9%)
of the patients are female
- Those individuals taking
benzodiazepines have primary conditions that are representative of all
CMClinic patients
- Well more than half (61.3%)
are primarily interested in treatment for a pain condition, 27.4 per cent
for a psychiatric condition and 11.3 per cent for a neurological condition
In all cases, patients remained under
the care of the referring doctor and all were examined in detail to understand
the effect of cannabinoid treatments on benzodiazepine use.
Canabo is also collecting data as to
what extent cannabis serves as a substitute or effective complement to
traditional opioid therapies and today's report is expected to be the first in
a series that examines the role of cannabis in modern therapies.
"To say that we're encouraged is
an understatement but there's a lot of work still to be done," added Dr.
Smith. "We hope to conduct formal trials both in-house and in
collaboration with others pending further analysis of what we believe to be one
of the most promising advancements in many years."
About Canabo Medical
Inc.
Canabo wholly owns and operates
Cannabinoid Medical Clinics, or CMClinics, Canada's largest physician led
referral-only clinics for medical cannabis. Established in 2014, Canabo has 15
clinics across Canada with several additional locations set to open in 2017.
Canabo operates referral-only medical
clinics dedicated to evaluating the suitability of prescribing, and monitoring
cannabinoid treatments for patients suffering from chronic pain and disabling
illnesses. Clinics operated by Canabo are staffed by physicians and qualified
health care practitioners specifically trained to assess patient suitability
for cannabinoid treatment, recommend treatment regimes, and monitor treatment
progress.
Forward-Looking Statements
Except for historical information,
this press release contains forward-looking statements, which reflect Canabo
Medical Inc.'s current expectations regarding future events. These
forward-looking statements involve known and unknown risks and uncertainties
that could cause Canabo's actual results to differ materially from those
statements. Those risks and uncertainties include, but are not limited to, our
ability to access capital, the successful and timely completion of opening
clinics, regulatory changes, competition, approvals and other business and
industry risks.
The forward-looking statements in
this press release are also based on several assumptions which may prove to be
incorrect. Forward-looking statements contained in this press release represent
views only as of the date of this release and are presented for the purpose of
assisting potential investors in understanding Canabo's business, and may not
be appropriate for other purposes. Canabo does not undertake to update
forward-looking statements, whether written or oral, that may be made from time
to time by or on its behalf, except as required under applicable securities
legislation. Investors are cautioned not to rely on these forward-looking
statements and are encouraged to consult with a professional investment
advisor.
For further
information, please contact:
Ms. Madeline Whittaker
Telephone: +1 (902) 334-1700
www.canabocorp.com
Telephone: +1 (902) 334-1700
www.canabocorp.com
Watch the 420
Cannabis Investor video
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment